On the basis of the in vitro results and the ongoing phase II APR246/PRIMA-1MET trial in cancer patients, the compound was topically administered to two patients affected by AEC syndrome (a p63-related ectodermal dysplasia with mutations found in the sterile α-motif or transactivation-inhibitory domain and also characterised by alopecia and skin erosion), with a significative improvement in epidermal covering, thus suggesting an effect of the compound on defective wound healing [53]. The gene discussed is TP63; the disease is ectodermal dysplasia syndrome.